This information is intended only for healthcare professionals resident in the United Kingdom

Prescribing Information (PI) for Somavert® (pegvisomant) ​​​​​

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search
for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

Pfizer Ltd. accepts no responsibility for the content or services of the linked site other than the information relating to Pfizer medicines which it has provided or reviewed

United Kingdom

  • Somavert (pegvisomant) 10 mg powder and solvent for solution for injection 
  • Somavert (pegvisomant) 15mg powder and solvent for solution for injection 
  • Somavert (pegvisomant) 20mg powder and solvent for solution for injection 
  • Somavert (pegvisomant) 25mg powder and solvent for solution for injection 
  • Somavert (pegvisomant) 30mg powder and solvent for solution for injection 

Somavert (pegvisomant) 10 mg powder and solvent for solution for injection 

Somavert (pegvisomant) 15mg powder and solvent for solution for injection 

Somavert (pegvisomant) 20mg powder and solvent for solution for injection 

Somavert (pegvisomant) 25mg powder and solvent for solution for injection 

Somavert (pegvisomant) 30mg powder and solvent for solution for injection 

PP-SOM-GBR-1399. May 2026